The pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are immense – and soaring. So why are Safety & Pharmacovigilance departments lagging in their application of smart technology? John Price at Arriello looks at why more life science companies are not automating PV data capture and what the practical solutions are to meet demand.